TKNOAlpha Teknova, Inc.Healthcare · Drug Manufacturers - Specialty & Genericas of 2026-09-16
Horizon

Issued 2026-09-16 at $7.11 · now $7.11 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, TKNO has typically landed between $4.57 and $10.54 — a range of −35.7% to +48.2% from the issuance price $7.11.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

1,291 overlapping 1 month windows · 2021-06-252026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.756.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($7.11) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where TKNO has typically landed a month from the 2026-09-16 close of $7.11 — the range is history, not a prediction.

$4.57worst · -35.7%$10.54best · +48.2%
  • now $7.11 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $6.86 (-3.5%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $5.65$8.07
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $4.57$10.54
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 1,291 windows spanning 2021-06-25 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2023-03-08−50.7%−50.7%+0.0%
2026-01-09−50.1%−50.1%+0.0%
2023-03-09−49.7%−49.7%+0.0%
3 best
2024-07-11+242.7%+0.0%+242.7%
2024-07-10+223.0%+0.0%+234.4%
2024-07-08+221.5%+0.0%+237.2%

1,291 overlapping windows · 2021-06-252026-09-16 · not cherry-picked

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~6 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
40%
−12.3%
n=5
Feb
40%
−6.4%
n=5
Mar
20%
−16.0%
n=5
Apr
40%
−7.3%
n=5
May
40%
+21.8%
n=5
Jun
40%
−10.5%
n=5
Jul
33%
+25.4%
n=6
Aug
33%
−2.8%
n=6
Sep
50%
+14.7%
n=6
Oct
40%
+5.3%
n=5
Nov
60%
+0.3%
n=5
Dec
60%
+17.4%
n=5

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$7$22026-03-06: 2 insider purchases, $143K — Lowell Matthew, Gunstream Stephen2026-03: 2 open-market purchases, $143K↑ buys↓ salesofficer Lowell Matthew — Purchase on 2026-03-06, filed 3 days after the tradedirector Gunstream Stephen — Purchase on 2026-03-06, filed 3 days after the trade
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling
2026-03-06Lowell MatthewofficerPurchase40,000 @ $2.19$88K+31.2% of holding+39.1%+212.8%168,376Form 4 · filed 3 days after the trade
2026-03-06Gunstream StephendirectorPurchase26,000 @ $2.15$56K+10.7% of holding+39.1%+212.8%269,497Form 4 · filed 3 days after the trade
2025-06-27DEMSKI MARTHA JdirectorSale8,000 @ $5.06$41K−40.0% of holding−9.6%−33.8%12,000Form 4 · filed 4 days after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

15 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-07-14DEMSKI MARTHA JdirectorOther acquisition12,00012,000Form 4
2026-07-14DEMSKI MARTHA JdirectorOther acquisition12,0000Form 4
2026-06-01Vos AlexanderdirectorAward / grant55,00055,000Form 4
2026-06-01ROBERTSON BRETTdirectorAward / grant55,00055,000Form 4
2026-06-01DEMSKI MARTHA JdirectorAward / grant55,00055,000Form 4
2026-02-15Lowell MatthewofficerAward / grant171,000171,000Form 4
2026-02-15Gunstream StephendirectorAward / grant429,000429,000Form 4
2026-02-15Terrill DamonofficerAward / grant148,000148,000Form 4
2025-06-17DEMSKI MARTHA JdirectorAward / grant54,30074,300Form 4
2025-06-17ROBERTSON BRETTdirectorAward / grant54,300102,472Form 4
2025-06-17Vos AlexanderdirectorAward / grant54,300102,472Form 4
2025-02-27ROBERTSON BRETTdirectorOther acquisition5,0005,000Form 4
2025-02-14Gunstream StephendirectorAward / grant393,663393,663Form 4
2025-02-14Terrill DamonofficerAward / grant137,808137,808Form 4
2025-02-14Lowell MatthewofficerAward / grant169,857169,857Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.